Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 北京九强生物技术股份有限公司是中国领先的临床体外诊断产品与服务供应商之一。公司创立于2001年,是以体外诊断产品的研发、生产和销售为主营业务的国家高新技术企业,拥有与国际同步发展的体外诊断系列产品。公司位于北京,注册资本为人民币58742.7728万元,2014年在创业板成功上市,股票代码为300406。作为国内体外诊断产业领军企业之一,公司致力打造最优体外诊断检测平台,目前拥有生化检测系统、血凝检测系统、发光检测系统、血型检测系统、POCT检测系统、病理检测系统和液体活检CTC。2020年,国药投资入股九强生物,共同布局医疗器械体外诊断领域。多年的稳定发展与完善积累,形成了遍及全国的营销和服务网络。公司一直专注体外诊断产品系统的研发,拥有一流的产品研发团队,建立起化学法、酶法(含循环酶法)、普通免疫比浊法、胶乳增强免疫比浊法、克隆酶供体酶免疫测定技术(CEDIA)、酶增强免疫测定技术(EMIT)等生化研发平台,同时也具备高水平的全液体血凝研发技术团队。2018年,以微柱凝胶法为核心的血型检测产品面市,标志着九强生物正式进军血型配血检测领域。在肿瘤病理领域,公司产品基本覆盖医院病理科日常肿瘤病理诊断和鉴别诊断所需试剂和免疫组化全自动化病理染色系统,并已建立起单克隆抗体制备技术、全自动化病理检测系统和荧光原位杂交等分子病理检测试剂、仪器研究平台,积极向分子病理诊断领域拓展并探索多元化服务和技术路线。公司研发中心是国家企业技术中心、“生化免疫诊断试剂北京市工程实验室”。同时,公司是CysC国家标物的共同研制者与制备企业,承担多项科技部与国家发改委课题。2021年,公司与中国人民解放军总医院共同合作完成的“军事作业环境心血管损伤防治体系的建立及应用”项目获得国家科学技术进步奖二等奖。为适应快速发展的需要,公司建立了国际一流的产品生产环境及生产管理流程,秉承“质量第一”的准则,向市场提供涵盖临床生化及血液领域的高品质临床检测项目,能针对不同目标客户提供多元化的临床诊断解决方案。同时,公司更加重视终端的用户体验,遍及全国的技术服务团队,保证在第一时间为用户解决疑难,提供完备的技术服务支持。“与巨人同行”。自2013年起,九强生物与雅培、罗氏、日立、迈瑞等国内外知名企业陆续建立起生化战略合作关系,与雅培签署的《技术许可和转让合作协议》更是开创了中国IVD企业技术输出的先河。通过十多年的长足发展,九强生物已经成长为中国领先的体外诊断产品生产厂商之一,并逐步在国际IVD市场上占有一席之地。“忠实诚信,充满激情”是九强生物的企业信条。如今,九强生物已成长为中国体外诊断产业的领军者之一,公司正通过不断的努力为全球用户提供更优质的产品与服务。 | ||||||||||||||||||||||||
Main Business | 生化诊断、血凝检测、血型检测和肿瘤病理诊断的研发、生产和销售 | ||||||||||||||||||||||||
Legal Representative | 邹左军 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 王建民 | ||||||||||||||||||||||||
Solicitors | 北京市金杜律师事务所 | ||||||||||||||||||||||||
Auditors | 致同会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 010-82247199 | ||||||||||||||||||||||||
Fax No | 010-82012812 | ||||||||||||||||||||||||
Website | www.bsbe.com.cn/ | ||||||||||||||||||||||||
jiuqiangzhengquan@bsbe.com.cn | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 30/10/2014 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.900 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 6.029 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 5.424B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |